Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Beamion BCGC-1: Zongertinib in Advanced HER2+ Cancers
NCT06324357Phase 2Recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2024
- Primary completion
- Jan 2029
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 10
01
Overview
Phase 2, randomised, open-label trial of zongertinib in breast cancer, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and 2 more (19 cohorts), sponsored by Boehringer Ingelheim. Primary endpoints: Dose-limiting toxicities up to 21 days and Objective response up to 50 months. Started Jun 2024; status: recruiting.
02
Drugs
zongertinib
03
Conditions
breast cancergastric adenocarcinomagastroesophageal junction adenocarcinomaesophageal adenocarcinoma (EAC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06324357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06324357.